CUL2

Across TCGA pan-cancer cohorts, CUL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CUL2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CUL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CUL2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where CUL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.363	0.803	.002	39	view →
LSCC	OS	Median	All	0.792	0.944	.005	24	view →
PDAC	OS	Tertile	IV	0.443	0.973	.024	12	view →
HNSC	OS	Quartile	III,IV	0.886	0.605	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CUL2–LUAD (OS)

Open the LUAD breakdown →